Technical Analysis for XCUR - Exicure, Inc.

Grade Last Price % Change Price Change
D 0.64 -2.59% -0.02
XCUR closed down 2.59 percent on Monday, March 18, 2024, on 6 percent of normal volume. It was able to find support at its 50 day moving average.
Earnings due: Mar 25
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
50 DMA Support Bullish 0.00%
New Uptrend Bullish 0.00%
Gapped Down Weakness 0.00%
Crossed Above 20 DMA Bullish -2.59%
Crossed Above 50 DMA Bullish -2.59%
Fell Below 50 DMA Bearish 4.75%
Spinning Top Other 4.75%
Inside Day Range Contraction 4.75%
Gapped Down Weakness 4.75%

   Recent Intraday Alerts

Alert Time
20 DMA Resistance about 13 hours ago
10 DMA Resistance about 15 hours ago
Gap Down Closed about 16 hours ago
Reversed from Down about 16 hours ago
20 DMA Support about 16 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Exicure, Inc. Description

Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Psoriasis Messenger RNA Netherton Syndrome Oncology Applications

Is XCUR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.5
52 Week Low 0.3647
Average Volume 422,211
200-Day Moving Average 0.76
50-Day Moving Average 0.63
20-Day Moving Average 0.65
10-Day Moving Average 0.66
Average True Range 0.07
RSI (14) 49.49
ADX 35.2
+DI 19.53
-DI 18.71
Chandelier Exit (Long, 3 ATRs) 0.60
Chandelier Exit (Short, 3 ATRs) 0.72
Upper Bollinger Bands 0.74
Lower Bollinger Band 0.57
Percent B (%b) 0.42
BandWidth 27.18
MACD Line 0.01
MACD Signal Line 0.02
MACD Histogram -0.0066
Fundamentals Value
Market Cap 5.53 Million
Num Shares 8.65 Million
EPS 1.77
Price-to-Earnings (P/E) Ratio 0.36
Price-to-Sales 0.21
Price-to-Book 0.53
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.73
Resistance 3 (R3) 0.73 0.71 0.72
Resistance 2 (R2) 0.71 0.68 0.71 0.71
Resistance 1 (R1) 0.67 0.67 0.69 0.67 0.70
Pivot Point 0.65 0.65 0.66 0.65 0.65
Support 1 (S1) 0.61 0.62 0.63 0.61 0.58
Support 2 (S2) 0.59 0.61 0.59 0.57
Support 3 (S3) 0.55 0.59 0.57
Support 4 (S4) 0.55